Internet Archive Scholar

Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT

Niklaus Schaefer, Gerd Grözinger, Maciej Pech, Thomas Pfammatter, Cigdem Soydal, Dirk Arnold, Frank Kolligs, Geert Maleux, Graham Munneke, Bora Peynircioglu, Bruno Sangro, Helena Pereira (+3 others)
2022 Clinical colorectal cancer  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.6 MB)
https://web.archive.org/web/20220923231850/https://www.clinical-colorectal-cancer.com/article/S1533-0028(22)00100-1/pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Transarterial radioembolisation (TARE) with Yttrium-90 resin microspheres is a treatment option for patients with metastatic colorectal cancer in the liver (mCRC). A better understanding of the prognostic factors and treatment application can improve survival outcomes. We analysed the safety and effectiveness of 237 mCRC patients included in the prospective observational study CIRSE Registry for SIR-Spheres Therapy (CIRT) for independent prognostic factors for overall survival (OS),
more » ... free survival (PFS) and hepatic progression-free survival (hPFS) using the Cox proportional-hazard model. The median OS was 9.8 months, median PFS was 3.4 months and median hPFS was 4.2 months. Independent prognostic factors for an improved overall survival were the absence of extra-hepatic disease (P= .0391), prior locoregional procedures (P= .0037), an Aspartate transaminase to Platelet Ratio Index (APRI) value of ≤0.40 (P< .0001) and International Normalized Ratio (INR) ≤1 (P= .0078). Partition model dosimetry resulted in improved OS outcomes compared to the body surface area model (P = .0120). Independent predictors for PFS were APRI >0.40 (P = .0416) and prior ablation (P = .0323), and for hPFS these were 2 to 5 tumor nodules (P = .0148), Albumin-bilirubin (ALBI) grade 3 (P = .0075) and APRI >0.40 (P = .0207). During the study, 95 of 237 (40.1%) patients experienced 197 adverse events, with 28 of 237 (11.8%) patients having a grade 3 or higher adverse events. Including easy-to-acquire laboratory markers INR, APRI, ALBI and using partition model dosimetry can identify mCRC patients that may benefit from TARE.
doi:10.1016/j.clcc.2022.09.002 pmid:36270925 fatcat:dmimptedzrc55amkanzarract4
Open Access
Citation

Niklaus Schaefer, Gerd Grözinger, Maciej Pech, Thomas Pfammatter, Cigdem Soydal, Dirk Arnold, Frank Kolligs, Geert Maleux, Graham Munneke, Bora Peynircioglu, Bruno Sangro, Helena Pereira, Bleranda Zeka, Niels de Jong, Thomas Helmberger. "Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT." Clinical colorectal cancer (2022)